Charles River Laboratories Acquires WIL Research

Apr 04 2016

Charles River has acquired WIL Research, a premier provider of safety assessment and contract development and manufacturing (CDMO) services to biopharmaceutical and agricultural and industrial chemical companies worldwide. Acquiring WIL Research will enhance our position as a leading global early-stage contract research organization (CRO) by strengthening our ability to partner with global clients across the drug discovery and development continuum. This exciting expansion provides our clients with greater capacity, a deeper pool of knowledge, global facilities and more options for the conduct of studies, delivered with the same personal attention and superior service they are accustomed to.

Read the press release »

Watch a video about the effects of this integration on our science, relationships and employees »

Meet the new team members »

Learn more about our safety assessment capabilities »


Please see the Frequently Asked Questions below for more information.

Why did you do this deal?

We believe that this transaction offers a compelling value proposition for our clients:

  • Clients will be able to take advantage of our broader portfolio as WIL Research’s expertise in specialty safety assessment services and bioanalysis, as well as Contract Development and Manufacturing (CDMO) services are added.
  • WIL Research provides safety assessment capacity with strategically located facilities to support current and future global client requirements, including continental Europe.

This acquisition provides enhanced services, capabilities and capacity for the growing biotechnology client base. Together we provide clients the opportunity to partner with a single fully integrated CRO across the drug discovery and development continuum.

Do the two Companies share similar values?
What will happen to the WIL Research company name?
What does this mean for me and my relationship with Charles River and/or WIL Research?
I am in the process of signing a new contract with WIL Research – how does this acquisition affect that?